Treating and Assessing Treatment Response: AL Amyloidosis
This activity is supported by an educational grant from Janssen and Alexion.
Overview
TARGET AUDIENCE
This educational activity is intended for members of cardiology and oncology health care teams who treat patients with amyloidosis, including cardiologists, hematologists/oncologists, nurse practitioners, and PAs.
PROGRAM OVERVIEW
This interactive module features leading amyloidosis faculty using compelling cases to discuss the latest in treatment for AL amyloidosis.
LEARNING OBJECTIVES
Upon completion of this course, the learners should be able to:
- Outline approved therapeutic options for the management of AL
- Choose appropriate therapy for the patient with AL
- Incorporate necessary multidisciplinary management strategies for patients with AL
FACULTY
Morie A. Gertz, MD, MACP
Consultant, Division of Hematology
Roland Seidler Jr. Professor, Department of Medicine
Mayo Clinic
Rochester, MN
Daniel Lenihan, MD
Founder and Immediate Past President
International Cardio-Oncology Society
Director, Cardio-Oncology Program and Heart Failure Clinic
Cape Cardiology
Cape Girardeau, MO
Jennifer Liu, MD, FACC
Chief, Cardiology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Giovanni Palladini, MD, PhD
Amyloidosis Research and Treatment Center
Department of Molecular Medicine
University of Pavia
Pavia, Italy
PLANNING COMMITTEE
Morie A. Gertz, MD, MACP
Consultant, Division of Hematology
Roland Seidler Jr. Professor, Department of Medicine
Mayo Clinic
Rochester, MN
Daniel Lenihan, MD
Founder and Immediate Past President
International Cardio-Oncology Society
Director, Cardio-Oncology Program and Heart Failure Clinic
Cape Cardiology
Cape Girardeau, MO
Jennifer Liu, MD, FACC
Chief, Cardiology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Giovanni Palladini, MD, PhD
Amyloidosis Research and Treatment Center
Department of Molecular Medicine
University of Pavia
Pavia, Italy
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
INSTRUCTIONS FOR PARTICIPATION AND CREDIT
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pretest, completing the activity, and completing the posttest and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Technical Requirements: http://www.francefoundation.com/general-requirements.html
- Credit fulfillment
- If you are requesting AMA or a certificate of participation your certificate will be available for download.
ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and the International Cardio-Oncology Society.
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the International Cardio-Oncology Society. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
PHYSICIAN CREDIT DESIGNATION
The France Foundation designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other healthcare professionals completing this course will be issued a statement of participation.
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and the International Cardio-Oncology Society (IC-OS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and IC-OS disclose all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.
Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
|
Name of Individual |
Role in Activity |
Name of Commercial Interest(s) |
Nature of Relationship(s) |
Mechanism(s) implemented to resolve conflict of interest |
|
Daniel Lenihan, MD |
Planning Committee Member, Faculty |
1. AstraZeneca, BMS, Clementia, Eidos, OncXerna 2. Myocardial Solutions
|
1. Non-CE Consulting 2. Contract research |
The financial relationship with Myocardial Solutions ended in September 2021 All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Giovanni Palladini, MD, PhD |
Planning Committee Member, Faculty |
1. Alexion, Argobio, Gate Bioscience, Janssen-Cilag, Pfizer, Protego, Prothena, Sebia, Siemens, The Binding Site 2. Caelum, European Myeloma Network, Janssen, Novo Nordisk, Oncopeptides, Pfizer, Prothena, Siemens, The Binding Site, Zentalis |
1. Non-CE Consulting 2. Contract Research |
The financial relationship with Oncopeptides ended in 2021 All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Heather Tarbox, MPH |
TFF Staff |
No relevant financial disclosures |
NA |
NA |
|
Jennifer Liu, MD, FACC |
Planning Committee Member, Faculty |
1. Axiom, Johnson and Johnson |
2. Data Safety Monitoring Advisory Board,Research grant |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Meghan Macdonald |
TFF Staff |
No relevant financial disclosures |
NA |
NA |
|
Morie A. Gertz, MD, MACP |
Planning Committee Member, Faculty |
1. Abbvie, Alnylym, Aptitude Healthgrants, Ashfield, Celgene, i3Health, Ionis/Akcea, Janssen, Johnson & Johnson, Juno, Physicians Education Resource, Prothena, Research to Practice, Sanofi, and Sorrento. |
1. Non-CE Consulting |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Patrick Harty, PhD |
Planning Committee Member, TFF Content Reviewer |
No relevant financial disclosures |
NA |
NA |
|
Stephen Casselli |
IC-OS Staff |
No relevant financial disclosures |
NA |
NA |
DISCLOSURE OF UNLABELED USE
TFF and IC-OS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-OS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Janssen and Alexion.
DISCLAIMER
The France Foundation and the International Cardio-Oncology Society present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the International Cardio-Oncology Society, and the commercial supporter(s) assume no liability for the information herein.
COPYRIGHT INFORMATION
Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission
PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.
CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.